[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:multiple-myeloma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":314,"states":354},"Multiple Myeloma",306,272,[8,16,23,29,36,42,49,55,61,67,73,79,85,91,98,104,110,116,122,128,134,140,146,152,158,164,170,176,182,188,194,200,206,212,218,224,230,236,242,248,254,260,266,271,278,284,290,296,302,308],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06121843","A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and\u002For Refractory Multiple Myeloma",[12],"Phase 1","RECRUITING","2026-08-26T02:15:36.077529Z","2026-07-19T19:36:05.123361Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05714839","A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments",[20],"Phase 1\u002FPhase 2","2026-08-26T02:19:16.454910Z","2026-07-19T19:36:05.123058Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05137054","A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments",[12],"2026-08-26T02:17:14.343713Z","2026-07-19T19:36:05.119007Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07258511","A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma",[33],"Phase 3","2026-08-26T02:16:45.157238Z","2026-07-19T19:36:05.066496Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05651932","A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma",[12],"2026-08-26T02:19:13.549512Z","2026-07-05T05:32:16.808777Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT05405387","Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant",[46],"Phase 2","2026-08-26T02:17:32.059863Z","2026-07-05T05:32:16.799414Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06465316","Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma",[12],"2026-08-26T02:18:02.701182Z","2026-07-05T05:32:16.756683Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06106945","AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma",[20],"2026-08-26T02:19:12.219640Z","2026-07-05T05:32:16.743869Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06158841","Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma",[33],"2026-08-26T02:15:31.806698Z","2026-07-05T05:32:16.743520Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06993675","Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)",[46],"2026-08-26T02:17:24.721169Z","2026-07-05T05:32:16.728555Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07200102","Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma",[12],"2026-08-26T02:18:25.327036Z","2026-07-05T05:32:16.663314Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06066359","Ph I\u002FII Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR\u002FIL-15 for R\u002FR Myeloma",[20],"2026-08-26T02:17:58.890423Z","2026-06-18T04:29:21.268683Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07518186","A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma",[33],"2026-08-26T02:15:20.225313Z","2026-06-06T00:48:49.527187Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":96,"content_modified":97},"NCT04211259","Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization",[95],"Early Phase 1","2026-08-26T02:19:04.543908Z","2026-05-29T15:36:40.231775Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT07479979","Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and\u002For Refractory Multiple Myeloma",[20],"2026-08-26T02:18:35.425468Z","2026-05-29T15:36:40.195056Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT07555938","Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma",[33],"2026-08-26T02:15:00.557154Z","2026-05-29T15:36:40.191720Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT07053436","Horizon Two: HR NDMM (MMRC-100)",[46],"2026-08-26T02:17:59.904383Z","2026-05-29T15:36:40.182475Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05561387","Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment",[33],"2026-08-26T02:16:49.565137Z","2026-05-29T15:36:40.174196Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07581704","Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma",[12],"2026-08-26T02:19:14.560989Z","2026-05-13T02:55:06.792905Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT07227311","A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)",[46],"2026-08-26T02:16:47.762107Z","2026-05-13T02:55:06.679732Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT07382739","A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) \"PRIME-EMD-PMD\"",[46],"2026-08-26T02:15:52.238965Z","2026-05-05T02:47:14.272138Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT06375044","Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma",[12],"2026-08-26T02:15:42.447052Z","2026-05-05T02:43:29.730522Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT07409246","A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)",[12],"2026-08-26T02:17:17.791881Z","2026-05-05T02:43:29.728077Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT07099391","A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma",[20],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:29.702038Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT06115135","A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed\u002FRefractory Multiple Myeloma",[46],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:29.700243Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT04973605","A Phase 1b\u002F2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma",[20],"2026-08-26T02:19:28.327680Z","2026-05-05T02:43:29.683738Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT05789303","Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma",[46],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:29.682294Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT05231629","Sequential Therapy in Multiple Myeloma Guided by MRD Assessments",[46],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:29.679167Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT06997081","ERd Combination Treatment in Newly Diagnosed Multiple Myeloma",[46],"2026-08-26T02:15:49.658025Z","2026-05-05T02:43:29.649848Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":192,"content_modified":193},"NCT05850234","AZD0120 in Relapsed\u002FRefractory Multiple Myeloma (DURGA-1)",[20],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:29.528669Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":198,"content_modified":199},"NCT05312255","Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma",[],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:29.474937Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT07075510","Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders",[20],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:29.371668Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT07222761","A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed\u002FRefractory Multiple Myeloma (RRMM)",[33],"2026-08-26T02:17:52.450442Z","2026-05-05T02:43:29.365287Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT06209606","Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma",[95],"2026-08-26T02:16:03.788292Z","2026-05-05T02:43:29.330420Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT06376526","IMMUNOPLANT for Newly Diagnosed Multiple Myeloma",[46],"2026-08-26T02:18:56.409949Z","2026-05-05T02:43:29.230882Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":228,"content_modified":229},"NCT05530421","Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed\u002FRefractory Multiple Myeloma",[46],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:29.229063Z",{"nct_id":231,"title":232,"phases":233,"status":13,"updated_at":234,"content_modified":235},"NCT05847569","Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma",[46],"2026-08-26T02:15:04.877798Z","2026-05-05T02:43:29.200086Z",{"nct_id":237,"title":238,"phases":239,"status":13,"updated_at":240,"content_modified":241},"NCT05972135","Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",[46],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:29.195822Z",{"nct_id":243,"title":244,"phases":245,"status":13,"updated_at":246,"content_modified":247},"NCT05776979","Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients",[46],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.189075Z",{"nct_id":249,"title":250,"phases":251,"status":13,"updated_at":252,"content_modified":253},"NCT06313502","High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders",[12],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:29.074964Z",{"nct_id":255,"title":256,"phases":257,"status":13,"updated_at":258,"content_modified":259},"NCT05730036","A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed\u002FRefractory Multiple Myeloma",[33],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:29.071876Z",{"nct_id":261,"title":262,"phases":263,"status":13,"updated_at":264,"content_modified":265},"NCT05208307","Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma",[46],"2026-08-26T02:17:40.683658Z","2026-05-05T02:43:29.069274Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":114,"content_modified":270},"NCT05192122","Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD",[12],"2026-05-05T02:43:29.046999Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":276,"content_modified":277},"NCT07101445","Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial",[275],"Phase 4","2026-08-26T02:19:07.104270Z","2026-05-05T02:43:29.045673Z",{"nct_id":279,"title":280,"phases":281,"status":13,"updated_at":282,"content_modified":283},"NCT03761108","Phase 1\u002F2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma",[20],"2026-08-26T02:18:21.216897Z","2026-05-05T02:43:29.029303Z",{"nct_id":285,"title":286,"phases":287,"status":13,"updated_at":288,"content_modified":289},"NCT03909412","Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma",[12],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:28.900710Z",{"nct_id":291,"title":292,"phases":293,"status":13,"updated_at":294,"content_modified":295},"NCT05862012","Study of ISB 2001 in Relapsed\u002FRefractory Multiple Myeloma (TRIgnite-1)",[12],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:28.888040Z",{"nct_id":297,"title":298,"phases":299,"status":13,"updated_at":300,"content_modified":301},"NCT07200089","Recombinant Human IL-7 (NT-I7) in Relapsed\u002FRefractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)",[12],"2026-08-26T02:17:03.534765Z","2026-05-05T02:43:28.869752Z",{"nct_id":303,"title":304,"phases":305,"status":13,"updated_at":306,"content_modified":307},"NCT06976476","Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia",[46],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.845856Z",{"nct_id":309,"title":310,"phases":311,"status":13,"updated_at":312,"content_modified":313},"NCT04643002","Isatuximab in Combination With Novel Agents in RRMM - Master Protocol",[20],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:28.835475Z",[315,319,322,326,330,333,336,339,342,345,348,351],{"biomarker":316,"count":317,"slug":318},"TP53 Gene",7,"tp53-gene",{"biomarker":320,"count":317,"slug":321},"Tumor Necrosis Factor Receptor Superfamily Member 17","tumor-necrosis-factor-receptor-superfamily-member-17",{"biomarker":323,"count":324,"slug":325},"MBD5 wt Allele",6,"mbd5-wt-allele",{"biomarker":327,"count":328,"slug":329},"t(11;14)",5,"t-11-14",{"biomarker":331,"count":332,"slug":331},"17p",3,{"biomarker":334,"count":332,"slug":335},"BCR\u002FABL1 Fusion Gene","bcr-abl1-fusion-gene",{"biomarker":337,"count":332,"slug":338},"Beta-2-Microglobulin","beta-2-microglobulin",{"biomarker":340,"count":332,"slug":341},"CD38 Gene","cd38-gene",{"biomarker":343,"count":332,"slug":344},"HLA Complex","hla-complex",{"biomarker":346,"count":332,"slug":347},"t(14;16)","t-14-16",{"biomarker":349,"count":332,"slug":350},"t(14;20)","t-14-20",{"biomarker":352,"count":332,"slug":353},"t(4;14)","t-4-14",[355,359,363,367,371,375,379,383,387,391,395,399,403,407,410,413,417,420,424,428,432,436,440,443],{"state":356,"count":357,"slug":358},"New York",102,"new-york",{"state":360,"count":361,"slug":362},"California",88,"california",{"state":364,"count":365,"slug":366},"Florida",80,"florida",{"state":368,"count":369,"slug":370},"Texas",75,"texas",{"state":372,"count":373,"slug":374},"North Carolina",71,"north-carolina",{"state":376,"count":377,"slug":378},"Georgia",67,"georgia",{"state":380,"count":381,"slug":382},"Massachusetts",64,"massachusetts",{"state":384,"count":385,"slug":386},"Ohio",60,"ohio",{"state":388,"count":389,"slug":390},"New Jersey",53,"new-jersey",{"state":392,"count":393,"slug":394},"Minnesota",47,"minnesota",{"state":396,"count":397,"slug":398},"Tennessee",46,"tennessee",{"state":400,"count":401,"slug":402},"Colorado",43,"colorado",{"state":404,"count":405,"slug":406},"Illinois",42,"illinois",{"state":408,"count":405,"slug":409},"Washington","washington",{"state":411,"count":405,"slug":412},"Wisconsin","wisconsin",{"state":414,"count":415,"slug":416},"Maryland",41,"maryland",{"state":418,"count":415,"slug":419},"Michigan","michigan",{"state":421,"count":422,"slug":423},"Arizona",39,"arizona",{"state":425,"count":426,"slug":427},"Missouri",37,"missouri",{"state":429,"count":430,"slug":431},"Pennsylvania",34,"pennsylvania",{"state":433,"count":434,"slug":435},"Virginia",31,"virginia",{"state":437,"count":438,"slug":439},"Oregon",30,"oregon",{"state":441,"count":438,"slug":442},"Utah","utah",{"state":444,"count":445,"slug":446},"Alabama",27,"alabama"]